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ABSTRACT
“Mini” allogeneic bone marrow transplants using non-myeloablative conditioning have reduced early treat-
ment-related mortalities, but graft-versus-host disease (GVHD) and graft rejection remain clinical problems.
Our preliminary studies indicated that low-dose busulfan conditioning and costimulatory blockade using
anti-CD154 monoclonal antibody (mAb) in combination with a pretransplantation “tolerating” dose of bone
marrow (BM) cells were sufficient to establish stable mixed-chimerism without GVHD when transplanting
moderate doses of T cell depleted (TCD)-BM from major histocompatibility complex (MHC) fully-mis-
matched donors (Adams AB, Durham MM, Kean L, et al. J Immunol. 2001;167:1103-1111). In this study, donor
splenocytes were administered before transplantation as a tolerating cell infusion with a conditioning regimen
consisting of low-dose busulfan and anti-CD154 mAb. We compared the ability of viable and apoptotic donor
cells of different ex vivo treatments and purified different donor cell populations (CD3, CD3, CD11b, and
CD11b splenocytes) to induce tolerance and enhance donor chimerism in a MHC mismatched model of
murine bone marrow transplantation. We found that mixed chimerism without GVHD was enhanced by
pretransplantation administration of viable allogeneic splenocytes and diminished in mice with prior exposure
to apoptotic/necrotic donor splenocytes. CD11b-enriched splenocytes more potently enhanced donor chi-
merism compared to unfractionated splenocytes or other splenocyte subsets. Mixed lymphocyte cultures
demonstrated that apoptotic stimulators overcame the immune-tolerating activity of anti-CD154 mAb and led
to increased interferon  and tumor necrosis factor  synthesis, increased proliferation of responder T cells,
and decreased production of interleukin-10. In conclusion, viable donor splenocytes administered before
transplantation in combination with costimulatory blockade induced tolerance and enhanced donor chimerism,
whereas pretransplantation administration of apoptotic/necrotic donor cells led to host T cell activation and
decreased overall donor engraftment.
© 2006 American Society for Blood and Marrow Transplantation
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dNTRODUCTION
Allogeneic bone marrow transplantation (BMT) is
ncreasingly and widely used for the treatment of
any malignant and severe non-malignant blood dis-
ases [1]. To decrease graft rejection and avoid high-
ose immunosuppressive chemotherapy or total body
rradiation conditioning regimens, a combination of dow-dose chemotherapy and costimulatory blockade
as been used to establish stable mixed chimerism
ith minimal toxicity and without graft-versus-host
isease (GVHD) [1-4]. Stable donor macrochimerism
ay transfer beneﬁcial donor immune responses to
umor and virus infection and ameliorate autoimmune
iseases [5]. Previous reports have shown that low-
ose irradiation and costimulatory blockade can in-
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J. Li et al.1240uce long-term stable mixed chimerism in allogeneic
MT, but this model required a large number of
onor BM cells and is clinically impractical [6]. To
ugment host-versus-graft tolerance and improve do-
or engraftment, different immunosuppressive agents
ave been used in combination with costimulatory
lockade with somewhat paradoxical results. The use
f cyclosporine or tacrolimus in combination with
ostimulatory blockade decreased donor engraftment
7-9]. These reports suggested that costimulatory
lockade induces an active process of host-versus-graft
olerance and that initial donor and host T cell acti-
ation after engagement of alloantigen may be an
mportant element in establishing stable mixed chi-
erism. Our previous published report showed that
dministration of low-dose busulfan and anti-CD154
onoclonal antibody (mAb) led to stable, busulfan
ose-dependent donor-engraftment after transplanta-
ion of as few as 2  107 BM cells (6.6  108/kg) [10].
lthough the exact mechanisms of tolerance after anti-
D154 mAb costimulatory blockade were not de-
cribed, we [4] and others [11-14] have reported that
olerance was mediated by regulatory T cells and by
eletion of host-type donor-reactive activated T cells.
evels of donor engraftment could be titrated by
hanging the number of donor BM cells [15] or busul-
an dose [10] in a model in which 2 doses of BM were
dministered, 1 dose given as a source of “tolerating”
lloantigen on day 6, before busulfan, and a second
ngrafting dose of donor BM given on day 0. Trans-
ation of this approach to clinical practice is limited by
he availability of large numbers of BM cells needed as
art of a pre-BMT presensitization process to induce
ost-versus-graft tolerance. As an alternative to day
6 administration of donor BM, infusion of donor
plenocytes led to donor-speciﬁc tolerance with pro-
onged donor skin graft survival [16], but the mecha-
ism whereby donor splenocytes induced host-versus-
raft tolerance or the particular donor cell populations
hat were tolerogenic have not been deﬁned.
To optimize donor chimerism using a limited
umber of donor BM cells and to create a platform of
table mixed chimerism from which to explore the
ntitumor activity of donor splenocyte infusion, we
ested a variety of different donor splenocyte prepa-
ations as a source for tolerating alloantigen coupled
ith a non-myeloablative conditioning regimen and
ostimulatory blockade in a mouse model of major his-
ocompatibility complex (MHC)-mismatched BMT.
e found that viable donor CD11b-enriched spleno-
ytes administered on day 6 before BMT resulted in the
ighest levels of donor chimerism, and that ex vivo
reatments that induced apoptosis in donor spleno-
ytes could completely abrogate mixed chimerism ob-
erved after costimulatory blockade. These data indi-
ate that apoptotic donor cells should be avoided in
olerating infusion of donor cells used in conjunction Aith costimulatory blockade in patients undergoing
on-myeloablative conditioning and allogeneic hema-
opoietic progenitor cell transplantation.
ETHODS
ice
B6.SJL (H-2Kb, CD45.1, CD90.2), congenic strains
f C57BL/6 (H-2Kb), BALB/c (H-2Kd CD45.2,
D90.2), and B10.BR (H-2Kk CD45.2, CD90.2) mice
ere purchased from The Jackson Laboratory (Bar
arbor, Me). Congenic strains expressing CD45.1,
D90.1, and CD45.2, CD90.1 on a C57BL/6 (H-
Kb) background were bred at the Emory University
nimal Care Facility (Atlanta, Ga). Mice for donor
M were 6-8 weeks old; mice for donor splenocytes
nd recipients were used at 8-10 weeks old.
onor Cell Preparation
BM and splenocyte harvest. Femora, tibia, and
pleens were isolated from donor mice. BM cells and
plenocytes were harvested from the bones and spleen,
espectively, with sterile RPMI-1640 containing 1%
eat-inactivated fetal calf serum (RPMI/FCS).
Cell subpopulation enrichment or depletion of BM and
plenocytes. BM cells and splenocytes in RPMI/FCS
ere blocked with anti-FcR 16/32 antibody (Pharmi-
en, San Diego, Calif), incubated with biotinylated
nti-CD3 antibody, washed once in RPMI/FCS, then
esuspended with streptavidinmicrobeads (Miltenyi Bio-
ech Gmbh, Bergisch Gladbach, Germany) according to
he manufacturer’s instructions. The CD3 cell frac-
ions of BM and splenocytes were separated from CD3
ell fractions using the VarioMACS columnC (Miltenyi
iotec, Auburn, CA). The efﬁciency of CD3 depletion
as 93.2%. “Untouched” T cells were isolated from
plenocytes by using a cocktail of biotinylated non-T cell
ntibodies (anti-CD11b, B220, DX5, and TER119) and
treptavidin microbeads. T cells were obtained as the
nbound fraction using an LS column in the Vario
ACs separation device (Miltenyi Biotech Gmbh).
verage purity of CD3 T cells was 93  2%. The
D11b cell and CD11b cell fractions were isolated
rom splenocytes stained with biotinylated anti-
D11b antibodies and streptavidin microbeads using
he Vario MACS column C. The average efﬁciency of
epletion (CD11b) and enrichment (CD11b) were
95% and 99%, respectively.
Splenocyte treatment. Splenocytes (107/mL) were
ultured in RPMI (10% FCS) with or without ﬂudara-
ine (20 g/mL; Berlex, Montville, NJ) for 24 hours
n 5% CO2 at 37°C [17], followed by 3 washes in
hosphate buffered saline (PBS) and fetal bovine se-
um (FBS). Fludarabine-treated (F-SP) cells and un-
reated SP cells were then used in the experiments.
lternatively, 24-hour untreated splenocytes were
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Apoptotic Cells Inhibit Tolerance in CD40-CD154 Blockade 1241reated with 7.5, 15, and 30 Gy (I-SP) using a single
raction from a cesium 137 source (irradiated) [18] or
reated with 2 nM S59 psoralen compound (Cerus
orporation, Concord, CA) at room temperature and
mmediately exposed to 3 J/cm2 UV-A light for 5 min
P-SP) [19].
onditioning Regimen and BM Transplantation
On the seventh (day 7), sixth (day 6), fourth
day 4), and second (day 2) days before BMT, the
ay of transplantation (day 0) and the sixth day after
ransplantation (day 6), recipient mice were given 500
g anti-CD154 mAb (hamster anti-mouse CD40L
Ab; MR1, Bioexpress, Lebanon, NH) intravenously.
ecipient mice were given 3  107 splenocytes intra-
enously on day 6 and busulfan at a dose of 20
g/kg body weight intraperitoneally on day 1. In
ddition, 2  107 T cell-depleted BM cells were ad-
inistered by tail vein injection on day 0 in a volume
f 0.2 mL (Figure 1A). Mice were maintained on oral
queous antibiotics (1.1 mg/mL neomycin sulfate and
000 U/mL polymyxin sulfate) for 4 weeks after
MT.
nalysis of Hematopoietic Engraftment
Peripheral blood (0.1 mL) was collected from the
ail vein at days 20, 30, 60, 90, 130, 160, 190, and 250
fter transplantation. For ﬂow cytometric analysis, red
lood cells were depleted by ammonium chloride ly-
is. Host- and donor-derived leukocytes and T cells
ere evaluated using mAbs for speciﬁc leukocyte
arkers expressed on congenic C57BL/6 and B10.BR
trains (CD45.2/ﬂuorescein isothiocyanate, CD45.1/
hycoerythrin [PE], H-2Kb-PE, CD3/peridinin chlo-
ophyll protein, CD90.1/peridinin chlorophyll pro-
ein, CD11b/allophycocyanin [APC], and CD90.2-
PC). Flow cytometry was performed on a 4-color
ACSCalibur (Becton Dickinson, San Jose, Calif).
iles containing 20 000-50 000 list mode events were
nalyzed with CellQuest software (Becton Dickinson).
ssessment of Survival and GVHD
n Transplant Recipients
All transplant recipients were evaluated for clinical
igns of GVHD by weight loss, posture, activity, fur
exture, and skin integrity [20,21] once or twice
eekly. The ear-punched mice from coded cages were
ssessed and graded from 0 to 2 for each criterion.
he sum of the ﬁve criteria scores yielded a clinical index
maximum index, 10). Survival was monitored daily.
poptosis Assessment and Mixed
ymphocyte Reaction
Splenocytes isolated from H-2Kb (CD45.1) and
-2Kk (CD45.2) mice were resuspended at a concen-ration of 1  107/mL in PBS. H-2Kk cells were 4rradiated with 7.5, 15, or 30 Gy and washed with 3%
BS-PBS. The cells were stained with Annexin V-PE
nd amino actinomycin D (Pharmingen, San Diego,
alif). Splenocytes isolated from H-2Kb were stained
ith 3 M 5-(and-6)-carboxy ﬂuorescein diacetate
uccinimidyl ester (CFSE; Molecular Probes, Eugene,
re) at room temperature for 5 minutes, washed twice
ith 10 vol of PBS and 3% FBS-PBS, and resus-
ended in RPMI (10% FCS) at 4  106/mL. H-2Kb
plenocytes (2  105) stained with CFSE were cocul-
ured with untreated (nonirradiated; 2  105) and
0-Gy irradiated (2  105) H-2Kk splenocytes in 96-
ell U-bottom plates, with or without the addition of
igure 1. Untreated splenocytes promoted donor engraftment.
, Experimental design. B10.BR (H-2kk, CD45.2, CD90.2) mice
eceived intravenously 500 g anti-CD154 mAb on days 7, 6,
4, and 2 before transplantation and on days 0 and 6 after
ransplantation. Busulfan 20 mg/kg was given intraperitoneally on
ay 1. In addition, 3  107 C57BL/6 congenic (CD45.1, H-2kb,
D90.1) splenocytes were infused on day6 and 2 107 C57BL/6
ongenic (CD45.1, H-2kb, CD90.2) TCD-BM was administered on
ay 0 intravenously. The transplantation experiment was repeated 3
imes and 5 mice underwent transplantation for each condition in
ach experiment. Peripheral blood was collected from the recipients
t days 30 and 60 after transplantation. Peripheral blood lympho-
ytes were stained with CD45.1, CD45.2, CD90.1, and CD90.2
nd analyzed by ﬂow cytometry. *P  .05 versus TCD-BM alone.
, Illustration of donor and host leukocytes and T cell gate. C,
onor cell percentage.0 g/mL anti-CD154 mAb. At 72 hours, the super-
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J. Li et al.1242atant were harvested for cytokine assays. The cells
ere harvested from 6-8 wells according to the exper-
ments, counted, stained by CD45.1-PE and CD3-
PC, and then assessed for CFSE dilution using a
ACS Aria instrument and FACS Diva software (BD
iosciences, San Jose, Calif). Proliferation cycles were
nalyzed by FlowJo Software (Tree Star, Inc., Ash-
and, Ore) and the division ratio (division cell number/
otal cell number) was calculated according to pub-
ished methods [17].
nalysis of Interleukin-10, Interferon-, and
umor Necrosis Factor  by Enzyme-linked
mmunosorbent Assay
Concentrations of interleukin-10 (IL-10), interfer-
n- (IFN-), and tumor necrosis factor 	 (TNF-	) in
he culture supernatant, isolated at 72 hours from
ixed lymphocyte reaction (MLR), were analyzed us-
ng OptEIA enzyme-linked immunosorbent assay kits
Pharmingen). Further, 96-well enzyme-linked immu-
osorbent assay plates were analyzed using a Spectra-
ax 340PC spectrophotometer (Molecular Devices,
unnyvale, Calif). Detection limits of IL-10, IFN-,
nd TNF-	 are 4, 15, and 5 pg/mL, respectively.
tatistical Analyses
Survival differences between different groups were
alculated with the Kaplan-Meier log-rank test in a
airwise fashion. Differences of GVHD and division
atio across groups were compared using the Mann-
hitney U test. Differences in levels of donor T cells
nd other parameters were compared using 1-way
nalysis of variance.
ESULTS
iable Donor Splenocytes Administered on Day
6 Enhanced Donor BM-derived Chimerism
ut Did Not Cause GVHD
We previously reported that 2 injections of BM
ells in combination with anti-CD154 mAb and low-
ose busulfan achieve macrochimerism and bidirec-
ional host-donor tolerance [10]. In this study we
ested the graft-promotion activity of donor spleno-
ytes, because this might better correspond to blood
ononuclear cells that could so easily be harvested
rom allogeneic human donor. Among B10.BR
CD45.2, CD90.2) mice that received the combina-
ion of splenocytes (CD45.1, CD90.1) from C57BL/6
ongenic mice on day 6 and 2  107 TCD-BM
CD45.1, CD90.2) or TCD-BM alone on day 0, all
ecipients survived and had steady body weight gain
nd no clinical signs of GVHD (data not shown).
onor-derived cells were detected in peripheral blood
t days 30 and 60 (Figure 1) after transplantation. The
requency of donor-derived cells in peripheral blood cas enhanced in recipients that received donor
plenocyte infusions on day 6 compared with recip-
ents of TCD-BM alone (Figure 1). Low numbers of
onor spleen-derived T cells were found in peripheral
lood at day 30 (1.0 %) and day 60 (1.5 %) after
ransplantation (data not shown), indicating that the
ontribution of the day 6 splenocyte infusion to
verall donor chimerism was minimal.
To test the importance of viability and immuno-
ompetence on the graft-promoting ability of donor
eukocytes administered on day 6, we infused un-
reated splenocytes, ﬂudarabine-treated splenocytes or
soralen, and UV-A-treated splenocytes on day 6
nd 2  107 TCD-BM from C57BL/6 congenic mice
n day 0 to B10.BR mice. Donor-derived cells were
etected in peripheral blood at days 30, 130, 190, and
50 (Figure 2) after transplantation. Recipients of un-
reated donor splenocyte infusions on day 6 signif-
cantly had higher levels of stable donor chimerism
ompared with the other recipients (Figure 2). The
verall frequency of donor-derived cells in peripheral
lood was not enhanced in recipients that received
reated donor splenocyte infusions on day 6 com-
ared with recipients of TCD-BM alone (Figure 2),
ndicating that procedures that compromised the via-
ility or immunocompetence of the pretransplanta-
ion infusion of donor leukocytes limited their graft-
romoting activity.
igure 2. Treated splenocytes had no donor engraft promotion.
he experimental design was similar to that shown in Figure 1,
xcept donor cells included 3  107 C57BL/6 congenic (CD45.1,
-2kb, CD90.1) untreated splenocytes, psoralen/UV-A treatment
P-SP), or after 24 hour of culture in media containing ﬂudarabine
F-SP) were infused on day 6 and 2  107 C57BL/6 congenic
CD45.1, H-2kb, CD90.2) TCD-BM was administered on day 0.
eripheral blood was collected from the recipients at days 30, 130,
90, and 250 after transplantation. Five mice underwent transplan-
ation for each condition, and the experiment was repeated twice.
eripheral blood lymphocytes were stained with CD45.1, CD45.2,
D90.1, and CD90.2 and analyzed by ﬂow cytometry. The per-
entage of donor cells is shown. *P  .05 versus TCD-BM alone.
t
d
d
m
i
d
d
b
t
d
C
s
c
C
o
B
(
m
t
w
g
c
s
m
c
p
n
s
C
g
T
p
t
f
l
r
h
w
(
a

c
s
c
(
c
n
a
F
i
u
C
p
t
T
w
2
e
A
A
D
p
m
t
r
t
m
w
u
s
2
w
f
g
i
a
s
d
e
t
t
c
s
o
F
w
i
d
(
n
r
a
c
i
F
m
g
G
s
d
1
r
i
T
p
d
Apoptotic Cells Inhibit Tolerance in CD40-CD154 Blockade 1243To further explore the role of host T cell alloreac-
ivity in donor cell engraftment, we used BALB/C as
onor mice and added additional immunosuppressive
rugs to the busulfan-containing conditioning regi-
en [1]. C57BL/6 congenic recipients were given 3
ntraperitoneal injections of ﬂudarabine 500 g/kg per
ay (low dose) or 1000 g/kg per day (high dose) on
ays 7, 6, and 5 in combination with 20 mg/kg
usulfan and anti-CD154 mAb. Adding ﬂudarabine to
he conditioning regimen had no additive effect on
onor chimerism in this transplant system (BALB/
¡C57BL/6), indicating that direct immunosuppres-
ion of the host is not a prerequisite of stable macro-
himerism (data not shown).
D11b-enriched Splenocytes Administered
n Day 6 Strongly Enhanced Donor
M-derived Chimerism
We previously noted that CD11b dendritic cell
DC) suppress alloimmune responses in a MHC-mis-
atched model of murine BMT [21]. We hypothesized
hat donor splenocytes enriched for CD11b cells
ould contain more CD11b DCs that could help
enerate tolerance in the recipients toward donor
ells. We predicted that CD11b-depleted donor
plenocytes enriched for the CD11b DC would aug-
ent alloreactivity and lead to lower levels of donor
himerism. To test engraft promotion of distinct cell
opulations of donor splenocytes, we infused alloge-
eic splenocytes depleted of T cells, T cell-enriched
plenocytes, CD11b-depleted splenocytes, and
D11b-enriched splenocytes from C57BL/6 con-
enic mice on day 6 in combination with 2  107
CD-BM on day 0 using a C57BL/6¡B10.BR trans-
lantation model, low-dose busulfan, and costimula-
ory blockade with a mAb to CD154. Chimerism data
rom the peripheral blood of the recipients were col-
ected by ﬂow cytometry (Figure 3A). As predicted,
ecipients of CD11b-enriched splenocytes had the
igher levels of donor BM engraftment compared
ith transplantation of TCD-BM alone at 20 days
P 
 .02) and 90 days (P 
 .03) after transplantation
nd recipients of the other manipulated splenocytes (P
.05; Figure 3B). Recipients of enriched splenic T
ells and T cell-depleted splenocytes did not have
igniﬁcantly higher levels of donor BM engraftment
ompared with recipients of untreated splenocytes
Figure 3B). Recipients of CD11b-depleted spleno-
ytes followed by TCD-BM had similar levels of do-
or BM engraftment as recipients of TCD-BM alone
t 20 and 90 days after transplantation (P  .05;
igure 3B). Donor spleen-derived cells did not signif-
cantly contribute to donor chimerism (Figure 3A,
pper panel, and data not shown). Recipients of donor
D11b-depleted splenocytes had a signiﬁcantly higher
ercentage of host T cells on days 20 and 90 after
ransplantation compared with other groups (Figure 3C). lhe percentage of donor BM-derived T cell population
as signiﬁcantly increased on day 90 compared with day
0 within groups, whereas host- and donor-derived my-
loid cells were relatively deceased (Figure 3C).
poptotic Donor Splenocytes Administered with
nti-CD154 mAb Reduced Engraftment by
onor Stem Cells
To further exclude direct effects of immunosup-
ressive drugs on host cells that might affect engraft-
ent, we compared different ex vivo methods of
reating the donor splenocytes infused on day 6,
easoning that treatments that limit the prolifera-
ive capacity of T cells or produce apoptotic cells
ight result in a tolerating donor cell population that
ould be more effective in promoting tolerance than
ntreated, viable donor immune cells [18,22]. Donor
plenocytes were exposed to 20 g/ml ﬂudarabine for
4 hours, irradiated (7.5, 15, and 30 Gy), or treated
ith psoralen and UV-A, conditions we previously
ound to limit T cell proliferation in vivo and produce
raded amounts of apoptosis [23]. We predicted that,
f tolerance was a passive process with donor-type
lloantigen cross-presented by host-type antigen-pre-
enting cells to host T cells, then apoptotic/necrotic
onor cells might be more effective in inducing tol-
rance than viable donor splenocytes. Surprisingly,
he levels of donor-derived chimerism in recipients of
olerating doses of untreated splenocytes was signiﬁ-
antly higher than that in all recipients of donor
plenocytes treated ex vivo with ﬂudarabine, psoralen,
r irradiation at all time points studied (P  .01;
igures 2, 4). The level of stable donor engraftment
as inversely proportional to the degree of the viabil-
ty of irradiated donor splenocytes administered on
ay 6, except for ﬂudarabine-treated splenocytes
Figures 4, 5A). Surprisingly, signiﬁcant levels of do-
or chimerism were observed in only 4 of 10 mice that
eceived 3 107 donor splenocytes irradiated to 30 Gy,
nd the 4 chimerism mice that received donor spleno-
ytes irradiated had the lowest levels of donor chimer-
sm (3.6  2.3%, at day 160 after transplantation).
urther, donor chimerism levels among the engrafted
ice were signiﬁcantly lower in all experimental
roups that received splenocytes irradiated to 15 or 30
y compared with TCD-BM alone at all time points
tudied (P  .01; Figure 4). There were no signiﬁcant
ifferences in the frequencies of chimeric mice (10 of
0) and in the level of chimerism among mice that
eceived TCD-BM plus F-SP, P-SP, or splenocytes
rradiated to 7.5 Gy compared with mice that received
CD-BM alone (Figures 2, 4). Thus, the pretrans-
lantation administration of donor splenocytes ren-
ered apoptotic/necrotic by irradiation doses 15 Gy
ed to lower levels of donor BM-derived chimerism.
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J. Li et al.1244roliferation Induced by Viable Alloantigen, But
ot Apoptotic Alloantigen, Was Suppressed
y Anti-CD154 mAb
To test the mechanism whereby viable and apo-
totic alloantigen inﬂuences donor engraftment, we
sed an MLR to measure the proliferative capacity of
cells responding to allogeneic splenocytes that were
ntreated or irradiated to induce apoptosis/necrosis.
ractions of apoptotic cells in the stimulator spleno-
ytes were 4% in control, untreated splenocytes and
6%, 41%, and 49% after exposure to 7.5, 15, and 30
y irradiation, respectively (Figure 5A). Using CFSE-
abeled responder T cells, we measured proliferation
igure 3. CD11b-enriched splenocytes administered on day 6 b
xperimental design was similar to that shown in Figure 1, except do
ntreated splenocytes, or manipulated splenocytes (CD3, CD3,
ongenic (CD45.1, H-2kb, CD90.2) TCD-BM was administered o
n days 20 and 90 after transplantation. Five mice underwent trans
xperiment was repeated twice. Peripheral blood lymphocytes wer
ytometry. A, Dot plot of peripheral blood cells. Upper panel, Phen
henotyped recipient/donor population cells after transplantation.
roups. C, Percentages of recipient and donor BM-derived CD3 Tf C57BL/6 T cells in MLR using irradiated or non- drradiated B10.BR stimulators. The proliferation of
FSE-labeled responder cells was decreased in MLR
sing untreated cells as stimulators in the presence of
nti-CD154 mAb compared with MLR without anti-
D154 mAb (division ratio, reduced from 0.5 0.1 to
.3  0.04; P  .01; Figure 5B). In contrast to the
mmunosuppressive effect of anti-CD154 on T cell
roliferation in MLR with unirradiated stimulators,
here was no difference in the proliferation of re-
ponders when using irradiated stimulators in the
resence or absence of anti-CD154 mAb (division
atio, 0.45 0.09 versus 0.45 0.08; Figure 5B). The
ddition of anti-CD154 mAb to MLR with nonirra-
ransplantation led to the highest level of donor engraftment. The
lls included 3  107 C57BL/6 congenic (CD45.2, H-2kb, CD90.1)
, and CD11b) were infused on day 6, and 2  107 C57BL/6
intravenously. Peripheral blood was collected from the recipients
ion for each condition in each experiment, and the transplantation
d with CD3, CD11b, CD45.2, and H-2Kb and analyzed by ﬂow
peripheral blood cells after transplantation. Left and right panels,
entage of donor BM-derived cells. *P  .05, comparisons between
nd CD11b myeloid cells after transplantation in different groups.efore t
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30 Gy) in the MLR resulted in the release of higher
evels of IFN- and TNF-	 into the culture media
nd the release of these proinﬂammatory cytokines
as not suppressed by the addition of anti-CD154
Ab. In contrast, the release of IFN- and TNF-	 in
LR using nonirradiated stimulators was fully or par-
ially inhibited by the addition of anti-CD154 mAb
Figure 5C). When using stimulators treated with
ower doses of irradiation (7.5 and 15 Gy), we ob-
erved that the addition of anti-CD154 mAb caused a
artial suppression of proliferation of MLR and a
ecrease in the production of proinﬂammatory cyto-
ines (IFN- and TNF-	; data not shown).
ISCUSSION
Recently, non-myeloablative, immunosuppressive
onditioning regimens have been used to establish
onor chimerism without the regimen-related toxicity
f traditional myeloablative transplants. However,
urrent non-myeloablative conditioning regimens re-
ult in signiﬁcant immune suppression after transplan-
ation. Patients treated with non-myeloablative con-
itioning usually develop full-donor chimerism when
ost-transplantation immunosuppressive drugs are
igure 4. Apoptotic splenocytes diminished donor engraftment.
he experimental design was similar to that shown in Figure 1,
xcept donor cells included 3  107 C57BL/6 congenic (CD45.1,
-2kb, CD90.1) untreated splenocytes, 7.5-, 15-, or 30-Gy irradi-
ted splenocytes (I-SP) were infused on day 6 and 2  107
57BL/6 congenic (CD45.1, H-2kb, CD90.2) TCD-BM was ad-
inistered on day 0 intravenously. The transplantation experiment
as repeated 3 times and 5 mice, excepting 10 mice in recipients of
rradiated donor splenocytes, underwent transplantation for each
ondition in each experiment. Peripheral blood was collected from
he recipients at days 30, 130, and 160 after transplantation. Pe-
ipheral blood lymphocytes were stained with CD45.1, CD45.2,
D90.1, and CD90.2 and analyzed by ﬂow cytometry. *P  .05
ersus TCD-BM alone. Donor cell percentage is presented.iscontinued 3-6 months after transplantation and are wt signiﬁcant risk for developing GVHD. An attractive
ew application of hematopoietic progenitor cell trans-
lantation would be to establish stable hematologic do-
or macrochimerism to induce bidirectional immuno-
ogic tolerance to facilitate organ transplantation and for
reatment of nonmalignant blood disorders. For this
linical application, complete ablation of host immunity
s undesirable. Previous reports have shown that low-
ose total body irradiation and costimulatory blockade
an induce long-term stable mixed chimerism as part
f allogeneic BMT, but this model required a large
umber of donor BM-derived cells that may be clin-
cally impractical [6]. To abrogate host-versus-graft
ffects and generate bidirectional tolerance with do-
or engraftment, different immunosuppressive agents
ave been used in combination with costimulatory
lockade. Surprisingly, the use of cyclosporine or ta-
rolimus in combination with costimulatory blockade
ecreased donor engraftment [7-9]. Donor engraft-
ent was elevated with increasing donor BM doses
hen using post-transplantation pharmacologic im-
unosuppression with costimulatory blockade [15,24-
6], and limited levels of chimerism were achieved.
hese reports suggest that costimulatory blockade in-
uces an active process of host-versus-graft tolerance
nd that initial donor and host T cell activation after
ngagement of alloantigen may be important elements
n establishing stable mixed chimerism.
In this study we explored the mechanisms whereby
onor splenocytes administered as a tolerating donor
ell infusion on day 6 combined with costimulatory
lockade (anti-CD154 mAb) conditioning improved
onor engraftment without inducing GVHD. We
ested the ability of donor splenocytes that had been
xposed to different methods of ex vivo treatment to
acilitate tolerance. Speciﬁcally, we compared ﬂudara-
ine-treated, irradiated, and psoralen-treated spleno-
ytes with the expectation that apoptotic donor cells
ould be more effective in inducing donor-speciﬁc
olerance in the host when combined with low-dose
usulfan and anti-CD154 costimulatory blockade
23]. Of note, ex vivo treatment with -irradiation,
soralen, or ﬂudarabine caused a substantial fraction
f donor lymphocytes to become apoptotic within 72
ours [23]. Several reports have shown that dying or
poptotic cells lead to immune tolerance in syngeneic
nd allogeneic transplantation [22,27-30]. The mech-
nisms of the tolerance are associated with suppres-
ion of maturation of DC [31], cross-tolerance by DC
29], release of anti-inﬂammatory cytokines by apo-
totic cells [32,33] and macrophages [34], and induc-
ion of regulatory T cells [28,35]. In the present study
e reasoned that a pretransplantation tolerating
ose of apoptotic donor splenocytes would be more
ffective than viable donor splenocytes in inducing
ost-versus-graft tolerance. Strikingly and some-
hat surprisingly, donor engraftment was decreased
b
t
a
p
s
a
n
b
w
c
a
t
T
r
a
a
c
d
c
g
r
v
a
d
t
d
a
a
C
o
i
v
t
p
T
o
d
c
c
F
A
p
s
w
c
a
I
M ti-CD1
J. Li et al.1246y administering ﬂudarabine-treated, psoralen-
reated, or -irradiated donor splenocytes as a toler-
ting dose of donor cells before transplantation com-
ared with a tolerating dose of untreated donor
plenocytes (Figures 2, 4). Donor splenocytes irradi-
ted with 15 and 30 Gy and administered on day 6
early completely abrogated subsequent engraftment
y donor BM, indicating that apoptotic donor cells
ere not only lost biological activity of donor spleno-
ytes in inducing host tolerance but also resulted in
ctivation of host immune responses that overcome
olerance induced by CD40-CD154 blockade [36,37].
hese results, using a low-dose busulfan conditioning
egimen, differ from ﬁndings in other reports that
poptotic donor cells induce tolerance in syngeneic
nd MHC-fully mismatched allogeneic recipients
onditioned by -irradiation [30,38]. The decrease in
onor chimerism seen when using apoptotic donor
ells in combination with costimulatory blockade sug-
igure 5. Proliferation induced by viable alloantigen, but not apop
nnexin V apoptotic cells 4 hours after exposure of splenocytes
roliferation histograms of H-2Kb T cells (2 105) 72 hours after in
plenocytes in the presence or absence of anti-CD154 mAb. Numb
ere set up per group, and experiments were repeated twice. The
alculated as 0-Gy stimulators without anti-CD154 (0.5  0.1), 0-G
nti-CD154 (0.45  0.08), and 30-Gy stimulators with anti-CD154
FN-, TNF-	, and IL-10 concentrations in supernatants from 72-
LRs that received anti-CD154 (solid bars) and MLRs without anests that the balance between tolerance and graft eejection depends on the presence of donor antigen or
iable donor cells in the context of signals that may
ctivate or block costimulatory signals on host-type or
onor-type APC. In vitro studies with MLRs to model
he events that occur after infusion of the tolerating
ose of donor splenocytes demonstrated that prolifer-
tion of responder lymphocytes stimulated by viable
llogeneic lymphocytes was suppressed by anti-
D154 mAb, whereas proliferation stimulated by ap-
ptotic stimulator splenocytes was enhanced or not
nﬂuenced by anti-CD154 mAb (Figure 5B). The in
itro data presented herein demonstrated that apopto-
ic cells can activate immune responses by inducing
roduction of proinﬂammatory cytokines such as
NF-	 and IFN- and by suppressing the production
f anti-inﬂammatory cytokine IL-10 (Figure 5C and
ata not shown). Although ﬂudarabine-treated spleno-
ytes contained a substantial number of apoptotic
ells, they were not as effective in blocking donor cell
lloantigen, was suppressed by anti-CD154 mAb. A, Percentage of
7.5, 15, or 30 Gy of irradiation (I-SP). B, Representative CFSE
of MLR with nonirradiated or 30-Gy irradiated H-2Kk stimulator
resent percentages of cells in each division peak. Six or 8 replicates
T cell precursor fractions in the different MLR conditions were
ulators with anti-CD154 (0.3  0.04), 30-Gy stimulators without
0.09). C, Enzyme-linked immunosorbent assay determinations of
LR from B. The cytokine concentrations were compared between
54 (open bars), *P  .05.totic a
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ant in the balance between tolerance and immune
ctivation [23]. Monk et al [39] reported that tolerance
nduced by anti-CD154 mAb is not due to costimula-
ory blockade but is dependent on removing activated
ost T cells directed by complement and Fc receptor.
lthough this mechanism of tolerance may be relevant
o organ transplants with short-term survival due to a
2-day half-life of anti-CD154 mAb in the mouse
irculation [40], the prolonged and stable donor chi-
erism lasting 9 months (Figure 2) in our studies
upport the ongoing participation of regulatory ele-
ents in maintain tolerance rather than a pure dele-
ion mechanism.
We further explored whether speciﬁc subpopula-
ions of the tolerating dose of donor splenocytes ad-
inistered before transplantation might be important
n helping to facilitate donor engraftment. Previous
eports showed that host CD4 T cells were necessary
or the effectiveness of anti-CD154 mAb costimula-
ory blockade [41-43]. We previously reported that
D11b-depleted BM (containing larger numbers of
onor CD11bDC) enhanced donor T cell engraft-
ent when cotransplanted with donor T cells,
hereas CD11b-enriched BM (containing larger
umbers of donor CD11bDC and suppressive my-
loid cells) was immunosuppressive [21]. In this study,
e found that CD11b-depleted donor splenocytes
dministered as a tolerating donor infusion on day 6
iminished subsequent donor BM engraftment,
hereas donor chimerism in recipients of a tolerating
ose of CD11b-enriched donor splenocytes was
igher than that of recipients of a tolerating dose of
nmanipulated splenocytes. The differences in the ef-
ects of CD11b-enriched splenocytes and CD11b-
eleted splenocytes on donor chimerism suggest that
D11b donor cells might delete, through comple-
ent-3 activation or Fc receptor, activated host T
ells that have bound the anti-CD154 antibody
39,44]. Of note, our results do not exclude a contri-
ution to graft facilitation by a direct immunosuppres-
ion effect by donor CD11b cells, including
D11b myeloid suppressor cells, CD11b DCs, or
D11b natural killer cells through local production
f inhibitory cytokines [21,45,46]. In contrast, the
D11b DCs present in CD11b-depleted donor
plenocytes may directly activate host-type CD8 T
ells and enhance graft rejection [21,36] because this
ell population has been reported to be incapable of
emoving activated host T cells via complement acti-
ation or Fc receptor phagocytic activity [39,44].
In conclusion, we found that viable donor
D11b-enriched splenocytes, administered as a tol-
rating dose 6 days before transplantation, with anti-
D154 mAb and low-dose busulfan conditioning,
ave a potent ability to facilitate subsequent donor
M engraftment. Donor splenocytes, irradiated toigh doses, activated allolymphocytic proliferation,
ncreased production of proinﬂammatory cytokines,
ecreased anti-inﬂammatory cytokines in vitro, and
ecreased engraftment levels proportional to the frac-
ion of apoptotic cells. Experiments in progress show
hat after transplantation infusion of donor spleno-
ytes to mice with stable bidirectional tolerance can
roduce a graft-versus leukemic effect (Li et al, in
reparation). Thus this model system creates a plat-
orm of stable mixed chimerism with reciprocal, bidi-
ectional graft, and host tolerance for subsequent
tudies of immunotherapy maneuvers that will in-
rease the overall graft-versus-leukemic effect of allo-
eneic BMT.
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